Daytona Street Capital LLC Makes New $1.36 Million Investment in Bristol Myers Squibb Company $BMY

Daytona Street Capital LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 25,247 shares of the biopharmaceutical company’s stock, valued at approximately $1,362,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Beacon Financial Strategies CORP bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $38,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $35,000. Finally, JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth approximately $36,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on BMY shares. UBS Group reiterated a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Guggenheim restated a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Morgan Stanley restated an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Barclays began coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Stock Down 0.5%

BMY stock opened at $59.30 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company’s 50 day simple moving average is $59.47 and its 200-day simple moving average is $52.85. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $121.07 billion, a P/E ratio of 17.19, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.